Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,865 across all filing types
Latest filing 2018-10-24 Earnings Release
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
Topline interim results of FALCON trial Part 1 in CF
Earnings Release Classification · 95% confidence The document is a press release dated October 24, 2018, announcing 'topline interim results' of a clinical trial (FALCON trial) for a novel combination treatment in cystic fibrosis (CF). It details preliminary safety, PK, and efficacy data (sweat chloride decrease, ppFEV1 increase). This structure—announcing key periodic results outside of a full annual or quarterly report filing—is characteristic of an Earnings Release (ER) or a specific clinical/research update. Since it focuses purely on announcing the results of a specific operational/research milestone rather than comprehensive financial performance for a period (which would be IR or 10-K), and it is a formal announcement from a listed company, it fits best under the Earnings Release category, which often includes operational highlights alongside financial snippets, or is used for major non-financial operational news releases. Given the options, 'ER' (Earnings Release) is the closest fit for a press release announcing key operational/trial results, even if it's not strictly a quarterly financial report. It is a direct announcement of performance metrics. It is not a full report (10-K, IR), a presentation (IP), or a transcript (CT). FY 2018
2018-10-24 English
Tussentijdse resultaten van het eerste deel van de FALCON studie in CF
Earnings Release Classification · 95% confidence The document is a press release dated October 24, 2018, announcing 'tussentijdse resultaten' (interim results) from Part 1 of the FALCON study concerning cystic fibrosis treatments. It details preliminary safety, PK, and efficacy data (changes in sweat chloride and ppFEV1%). This structure—an initial announcement of period-specific financial or clinical results, often released before a comprehensive quarterly report—aligns best with an Earnings Release (ER) or, given the clinical trial focus, potentially an Interim Report (IR) if it were a comprehensive financial document. However, since it is a specific announcement of clinical trial results and key data points, and not a full financial report (like a 10-Q or 10-K), it functions as an initial results announcement. In the context of biotech/pharma, these clinical updates often serve the same purpose as an ER for general market awareness. Since the document is a press release announcing key results and not a comprehensive 'Interim Report' (IR) or a full 'Annual Report' (10-K), and it is not a transcript (CT) or a presentation (IP), 'ER' (Earnings Release) is the most appropriate classification for a material results announcement. Q4 2018
2018-10-24 Dutch
POSITIVE TRIAL RESULTS WITH FILGOTINIB IN PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS BOTH PUBLISHED IN THE LANCET
Earnings Release Classification · 95% confidence The document is a press release dated October 22, 2018, announcing positive results from Phase 2 clinical trials (EQUATOR and TORTUGA) for the drug filgotinib, with the results being published in *The Lancet* and presented at the ACR/ARHP congress. This format—a formal announcement detailing key efficacy and safety data from clinical studies, often issued by pharmaceutical or biotech companies (Gilead and Galapagos)—is characteristic of an Earnings Release (ER) or a general press release announcing significant operational/clinical milestones. Since it focuses on the immediate release of key trial data and is not a comprehensive annual report (10-K), a quarterly report (IR), or a transcript (CT), the most fitting category is Earnings Release (ER), as these announcements often accompany or precede formal financial reporting periods, or function as major operational updates. However, given the specific focus on the *publication* of clinical trial results, it also strongly resembles an Investor Presentation (IP) or a general Regulatory Filing (RNS). Since it is a formal announcement of results rather than the presentation slides themselves (IP) or a mandatory regulatory filing (RNS), and it contains detailed results summaries, it functions similarly to an Earnings Release (ER) which communicates period performance highlights. Given the context of clinical trial data release, ER is the best fit among the provided options for a major operational/data announcement. Q4 2018
2018-10-23 English
POSITIVE TRIAL RESULTS WITH FILGOTINIB IN PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS BOTH PUBLISHED IN THE LANCET
Earnings Release Classification · 95% confidence The document is a press release dated October 22, 2018, announcing positive trial results for the drug filgotinib in Psoriatic Arthritis and Ankylosing Spondylitis. It details Phase 2 study endpoints (ACR20, ASDAS), safety profiles, and mentions that the full results were published in *The Lancet* and presented at the ACR/ARHP Annual Meeting. This content structure—announcing clinical trial results and referencing external publications/presentations—is characteristic of an Earnings Release (ER) or a general press release summarizing key findings, rather than the full financial report (10-K/IR) or the presentation itself (IP). Since it focuses on the immediate release of key clinical data and quotes management, 'ER' (Earnings Release) is the most appropriate classification, as clinical trial updates often accompany or substitute for standard quarterly earnings announcements in biotech/pharma, or it falls under the general category of a significant corporate announcement. Given the options, 'ER' (Earnings Release) captures the nature of a time-sensitive announcement of key operational/development milestones, which often includes clinical data summaries in this sector. It is not a Call Transcript (CT), Investor Presentation (IP), or a formal regulatory filing like 10-K or IR. Q2 2018
2018-10-23 English
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Galapagos NV, for the month of October 2018. It includes a press release as Exhibit 99.1 dated October 22, 2018. The document is relatively short (2821 characters) and primarily serves to submit a press release rather than containing detailed financial data or a full report. Form 6-K filings are typically used to furnish reports or other documents that foreign private issuers must make public under home country laws or exchange rules. This aligns with the definition of Regulatory Filings (RNS), which is a fallback category for miscellaneous filings that do not fit other specific categories and includes such SEC Form 6-K submissions. There is no indication that this document is an Annual Report, Earnings Release, or any other specific report type. Therefore, the appropriate classification is Regulatory Filings (RNS).
2018-10-23 English
PHASE 3 DATA ON FILGOTINIB IN BIOLOGIC-EXPERIENCED RHEUMATOID ARTHRITIS TO BE PRESENTED AT 2018 ACR/ARHP ANNUAL MEETING
Earnings Release Classification · 95% confidence The document is a press release issued jointly by Gilead Sciences and Galapagos NV. It announces the presentation of Phase 3 clinical trial data (FINCH 2) for the drug filgotinib at a medical conference (2018 ACR/ARHP Annual Meeting). This type of announcement, detailing clinical trial results and future presentation plans, is characteristic of an Earnings Release (ER) or a general press release related to operational/research updates. Since it focuses on announcing key results (efficacy and safety) immediately following data analysis, it aligns best with the 'Earnings Release' definition, which covers initial announcements of periodical financial/operational results, even if the results are clinical rather than purely financial. It is not a full Annual Report (10-K), an Interim Report (IR), or a transcript (CT). It is an announcement of results, not an announcement *about* a report being published (RPA). Q3 2018
2018-10-22 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.